G.ST ANTIVIRALS
G.ST Antivirals focuses on the development of antiviral drugs. G.ST Antivirals utilizes the viral dependency on the host cell metabolism and exploits this to design specific interventions counteracting viral nutrient supply.
G.ST ANTIVIRALS
Social Links:
Industry:
Biotechnology
Founded:
2019-01-01
Address:
Vienna, Wien, Austria
Country:
Austria
Website Url:
http://www.gst-antivirals.com
Total Employee:
1+
Status:
Active
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Amazon Organization Schema Google Apps For Business Google Google Cloud
Current Employees Featured
Founder
Investors List
IST cube
IST cube investment in Series A - G.ST Antivirals
Official Site Inspections
http://www.gst-antivirals.com
- Host name: acd89244c803f7181.awsglobalaccelerator.com
- IP address: 75.2.60.5
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "G.ST Antivirals"
Team - G.ST Antivirals
He is Co-Founder of G.ST Antivirals. Pascal Deschatelets, PhD. Dr. Deschatelets is a serial entrepreneur based in Massachusetts. He has co-founded Apellis Pharmaceuticals in …See details»
Life Sciences Directory: G.ST Antivirals GmbH
G.ST Antivirals GmbH Back to list. Facts. Founded 2019 Staff 3 Organization type RDM biotech/pharma Region Vienna Focus human health Profile. Similar companies in RDM …See details»
Team - G.ST Antivirals
Guido Gualdoni hat sowohl das Medizinstudium als auch ein PhD-Studium in Immunologie an der Medizinischen Universität Wien absolviert. Er ist Co-Gründer und CEO von G.ST Antivirals …See details»
G.ST Antivirals - Crunchbase Company Profile & Funding
G.ST Antivirals is a clinical-stage biotech company that develops broad-spectrum antivirals against infections of the respiratory tract. View contacts for G.ST Antivirals to access new …See details»
G.ST Antivirals reports start of Phase II trial and announces ...
Apr 9, 2024 For further information, please visit our website www.gst-antivirals.com or follow us on LinkedIn. Contact Guido Gualdoni, MD, PhD Chief Executive Officer G.ST Antivirals GmbH …See details»
G.ST Antivirals - Vienna BioCenter
G.ST Antivirals is dedicated to the development of therapies against different viruses applying an entirely novel approach of antiviral therapy. The MedUni Vienna spin-off utilizes the viral dependency on the host cell metabolism and …See details»
G.ST Antivirals reports positive Phase I trial results for 2-Deoxy-D ...
Jan 25, 2024 For further information, please visit our website www.gst-antivirals.com or follow us on LinkedIn. Contact. Guido Gualdoni, MD, PhD Chief Executive Officer G.ST Antivirals GmbH …See details»
G.ST Antivirals GmbH Company Profile | Wien, Wien, Austria ...
Find company research, competitor information, contact details & financial data for G.ST Antivirals GmbH of Wien, Wien. Get the latest business insights from Dun & Bradstreet.See details»
G.ST Antivirals - Products, Competitors, Financials, Employees ...
G.ST Antivirals is a clinical-stage biotech company focused on developing broad-spectrum antivirals for respiratory tract infections. The company's main offerings include a proprietary …See details»
xista Ventures: Detail
G.ST Antivirals was founded in 2019 to exploit these academic findings and develop therapeutics for the benefit of patients. We decided to invest in G.ST at a very early stage because of the …See details»
G.ST Antivirals reports start of Phase 2 trial and announces ...
9 April 2024 — Vienna, Austria — G.ST Antivirals, a clinical-stage biotechnology company applying innovative, host cell-based strategies to develop broad-spectrum antivirals against …See details»
G.ST Antivirals - Company Profile - Tracxn
Oct 31, 2024 G.ST Antivirals ranks 231st among 288 active competitors. 89 of its competitors are funded while 67 have exited. Overall, G.ST Antivirals and its competitors have raised over …See details»
G.ST Antivirals reports positive Phase I trial results for 2-Deoxy-D ...
Vienna, Austria, 25 January 2024 – G.ST Antivirals, a clinical-stage biotechnology company applying innovative, host cell-based strategies to develop broad-spectrum antivirals against …See details»
Biotech-Start-up G.ST Antivirals starts first clinical trial
May 10, 2022 About G.ST Antivirals. G.ST Antivirals is an Austrian start-up founded in 2019 as a spin-off from the Medical University of Vienna. The young company has its roots in extensive …See details»
G.ST Antivirals reports positive Phase I trial results
Jan 25, 2024 G.ST Antivirals reports positive Phase I trial results. Vienna, Austria, 25 January 2024 – G.ST Antivirals reported positive results from Phase I clinical trials on its lead …See details»
G.ST Antivirals reports start of Phase II trial and announces ...
Vienna, 09.04.2024: G.ST Antivirals reports start of Phase II trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer - • Phase II clinical trial started, 1st subject …See details»
Liberals, NDP pass bill to enact two-month GST holiday in House …
1 day ago The Liberals' GST holiday bill is one step closer to becoming law after it was passed by a majority of the House of Commons late Thursday night. The two-month tax break covers …See details»
News - G.ST Antivirals
May 9, 2022 Results of collaboration between G.ST Antivirals and Takeda Global Pathogen Safety are published in The Journal of Virus Eradication and substantiate efficacy of 2 …See details»
CFIB calls on Ottawa to compensate small firms for costs to …
2 days ago The Canadian Federation of Independent Business is asking the federal government to compensate small businesses for the costs to implement the two-month long GST holiday.. …See details»